ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CTXR
NCEL (28) ALLR (32) OPTH (46) DARE (36) ⌘ Pro Terminal →

Citius Pharmaceuticals Inc. (CTXR) — RQD Stock Rating Cockpit

$0.52 -7.10% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.51

Citius Pharmaceuticals Inc. (CTXR) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $14.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CTXR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CTXR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.52 (-7.10% 1D, market cap $14.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CTXR ranks #471 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CTXR compare to NCEL and ALLR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTXR carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NCEL (NewcelX Ltd.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $14.7M) and ALLR (Allarity Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M). Among the 5-stock peer group, CTXR leads on earnings multiple (N/A) while CTXR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CTXR?
▼

Per CTXR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001506251), Citius Pharmaceuticals Inc. generated $107.9M in revenue (-8.3% YoY), $0 in net income, and -$26.6M in free cash flow against $140.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.51 (-1.47%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (6)Whales (11)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-7.7% Base Target
$2 Bull$0 Base$0 Bear
📬 FREE CTXR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTXR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY CTXR SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
32
Grade E$0.48-12.5% Next Q
Q2 (-2Q)
35
Grade E$0.42+19% Next Q
Q3 (-1Q)
37
Grade E$0.50+4% Next Q
Current
40
Grade D-$0.52-7.4% Hist 90D α
Trajectory: E (32) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CTXR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CTXR currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.53) and Max Pain ($0.55) forces dealer call-delta covering toward $1.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTXR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CTXR Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
52.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE12% OF RANGE
L: $0$0.52H: $2
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CTXR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (30)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (40)

16/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like CTXR
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTXR)

  • ✓Walkthrough of CTXR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CTXR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -26.76%📐 HORIZONTAL RANGE
2026-11-03O $0.56H $0.56L $0.52C $0.52VOL 104.7K
RES: $0.92SUP: $0.34SMA50: $0.53SMA200: $0.65
$1.13$0.92$0.72$0.51$0.31RES $0.92SUP $0.34$0.522026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTXR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTXR Butterfly Map → + Track CTXR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -8.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CTXR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTXR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CTXR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTXR)

Health Care Rank #471 of 1015 ⚔️ NCEL vs CTXR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTXR vs. NCEL, ALLR, OPTH, DARE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Citius Pharmaceuticals Inc. (CTXR) ranks #471 by composite RQD confidence (40/100, grade D-) and #857 by equity capitalization ($14.4M). Within this direct 5-issuer industry benchmark cohort, CTXR leads on earnings valuation at N/A trailing P/E, while CTXR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OPTH currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with CTXR at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CTXR ACTIVE
Citius Pharmaceuticals Inc.
D- 40/100 — — -35.0% -7.10% $14.4M Benchmark Subject
NCEL
NewcelX Ltd.
E 28/100 — — -35.0% -5.27% $14.7M /ncel-vs-ctxr →
ALLR
Allarity Therapeutics Inc.
E 32/100 — — -35.0% -2.20% $13.8M /allr-vs-ctxr →
OPTH
Optimi Health Corp.
D 46/100 — — — -7.31% $13.8M /opth-vs-ctxr →
DARE
Dare Bioscience Inc.
D- 36/100 — 71.3% -35.0% +2.66% $13.8M /dare-vs-ctxr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001506251 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Citius Pharmaceuticals Inc. (CTXR) reported GAAP revenue of $107.9M (-8.3% vs. FY2024 revenue of $117.6M , and +4.9% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of -$26.6M, and free cash flow of -$26.6M (+5.8% YoY). On the balance sheet, CTXR closed FY2025 with $140.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $107.9M $0 -$26.6M -$26.6M $140.4M —
FY2024 (FY) 2024-09-30 $117.6M $0 -$28.2M -$28.2M $120.7M —
FY2023 (FY) 2023-09-30 $102.8M -$32.5M -$29.1M -$29.1M — —

3. CTXR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTXR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Citius Pharmaceuticals Inc. (NASDAQ: CTXR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $0.52 (-7.10% 1D, market cap $14.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, CTXR ranks #471 in composite RQD confidence.

How does CTXR compare to NCEL and ALLR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTXR carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NCEL (NewcelX Ltd.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $14.7M) and ALLR (Allarity Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $13.8M). Among the 5-stock peer group, CTXR leads on earnings multiple (N/A) while CTXR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTXR?

Per CTXR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001506251), Citius Pharmaceuticals Inc. generated $107.9M in revenue (-8.3% YoY), $0 in net income, and -$26.6M in free cash flow against $140.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTXR trading relative to its 50-day, 200-day, and 52-week technical levels?

CTXR last traded at $0.52 (-7.10% on volume of 104,681 shares), positioning the stock -1.89% below its 50-day simple moving average ($0.53) and -20.00% below its 200-day simple moving average ($0.65). Across its 52-week range of $0.37 to $1.60, CTXR sits at the 12.2% percentile with a 14-day RSI of 52.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.59).

Direct Sub-Reports: CTXR RQD Cockpit CTXR 12M Forecast CTXR Earnings & Move CTXR Dividends & DRIP CTXR Insiders & 13F CTXR Whale Options CTXR Profit Sankey CTXR News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

CTXR — Citius Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Citius Pharmaceuticals Inc. (CTXR) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $0.52 (-7.10% 1D, market capitalization $14.4M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Citius Pharmaceuticals Inc. (CTXR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. — for product detail or customer base.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Citius Pharmaceuticals Inc. (CTXR) reported $107.9M in annual revenue (up from $117.6M in FY2024, -8.3% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($102.8M revenue, -$32.5M net income) through FY2025, CTXR scaled operating cash flow to -$26.6M and free cash flow to -$26.6M, backed by $140.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 11/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $0.37 – $1.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links and no proprietary signals recorded. Sector and industry are Health Care and Biotechnology: Pharmaceutical Preparations, but the source data contains no sector-correlation metrics beyond the beta of 1.0 in the market data. — for upstream suppliers, downstream customers, or 2nd-order bottlenecks. An investor should watch for any future disclosure of licensing, manufacturing, or distribution dependencies, as these are absent from the current dataset.

  • Key Question #1: Can CTXR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $107.9M and free cash flow of -$26.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CTXR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CTXR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Citius Pharmaceuticals Inc. (CTXR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CTXR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CTXR Bull vs. Bear Conversation Board — What's Your Call at $0.52?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CTXR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CTXR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $0.69 (+32.7%)
📌 Pinned Debate

The RQD whale 13F flow pillar scores 13 of 20, the strongest of the five pillars, indicating the institutional positioning component is

Long CTXR at $0.52 targeting $0.69. The RQD whale 13F flow pillar scores 13 of 20, the strongest of the five pillars, indicating the institutional positioning component is the most supportive input in the rating.. Institutional whale score is 11/20 and the risk/reward vs. the $0.37 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

Both sides have a point here — CTXR's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.45 (-13.5%)
Spot @ $0.52

With ROIC at -35%, zero reported revenue across three fiscal years, and a Piotroski F-Score of 1/9, the financial data offers little cu

Fading this rally in CTXR at $0.52. With ROIC at -35%, zero reported revenue across three fiscal years, and a Piotroski F-Score of 1/9, the financial data offers little current evidence of a self-funding business.. With a beta of 1.0 and the stock sitting at $0.52 (52-wk range $0.37–$1.60), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%